By Michael J. Critelli | MakeUsWell Newsletter,
Six years ago this month, we were becoming aware of the SARS-Cov-2 virus, later described as the COVID-19 pandemic. It is usually remembered as a sudden viral catastrophe that demanded unprecedented emergency responses.
With the benefit of hindsight, however, it is equally accurate to describe COVID-19 as a metabolic stress test, one that revealed how profoundly baseline health shaped vulnerability to an acute infectious threat. The virus did not strike populations randomly. It exploited long-standing physiological weaknesses that had accumulated quietly for decades.
Few developments illuminate this reality more clearly than the later emergence of GLP-1 receptor agonists as powerful therapies for obesity, insulin resistance, and related cardiometabolic conditions. These medications were not widely available during the pandemic’s early years, but their rise helps clarify what kind of resilience was missing in 2020, and why emergency medicine alone could not fully compensate for it.